Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II
- PMID: 26816089
- DOI: 10.1007/s00520-016-3088-3
Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II
Abstract
Background: This study examined which patient- and physician-related factors influence guideline violations in adjuvant chemotherapy.
Patients and methods: In a prospective multi-center cohort study, patients with primary breast cancer were sampled consecutively over a period of four years (2009-2012). Patients completed a questionnaire prior to surgery and prior to adjuvant therapy. This questionnaire assessed health-related quality of life (QoL) using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, psychiatric co-morbidity with the Patient Health Questionnaire (PHQ), demographic characteristics (age, education), and the intensity of fear for chemotherapy. After surgery, a multi-professional team discussed recommendation for adjuvant chemotherapy, and this decision was documented in a database together with the indication for chemotherapy according to the German S3 guideline. This multi-professional team was blinded to that algorithm-based decision. Six months later, it was documented whether the patient had received adjuvant chemotherapy or not.
Results: Altogether, 857 patients were included in the study. In 391 of these patients, the tumor board (TB) decided to recommend chemotherapy. The most important reasons for not recommending chemotherapy were somatic co-morbidity not allowing adjuvant chemotherapy and age >75 years. Of these 391 patients, 73 (19 %) patients eventually did not receive chemotherapy. Deviations from the initial therapy decision were more frequent in older patients (≥75 years) with poor QoL. If the QoL was good, higher age was not related to deviation. There was some evidence that patients with higher education less frequently received chemotherapy (CT). Furthermore, if patients were very afraid of chemotherapy, deviations from the initial therapy decision were more likely. Co-morbidity and fear of CT were not related to the likelihood of deviating from the initial therapy decision.
Conclusion: Nineteen percent of patients eventually did not receive chemotherapy, despite guideline and TB recommendations. In these patients, this mainly occurred in association with poor QoL in elderly patients >75 years old. In the group with a chemotherapy recommendation, patients' fear of chemotherapy is another factor preventing patients from undergoing adjuvant chemotherapy.
Keywords: Breast cancer; Chemotherapy; Co-morbidity; Compliance; Guideline.
Similar articles
-
Which patient- and physician-related factors are associated with guideline adherent initiation of adjuvant endocrine therapy? Results of the prospective multi-centre cohort study BRENDA II.Breast Cancer. 2017 Mar;24(2):281-287. doi: 10.1007/s12282-016-0701-8. Epub 2016 May 19. Breast Cancer. 2017. PMID: 27193566
-
Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: Results from the prospective multicenter BRENDA II study.Breast J. 2019 May;25(3):386-392. doi: 10.1111/tbj.13231. Epub 2019 Apr 3. Breast J. 2019. PMID: 30945393 Clinical Trial.
-
Health-related quality of life in early breast cancer.Dan Med Bull. 2010 Sep;57(9):B4184. Dan Med Bull. 2010. PMID: 20816024
-
Quality-of-life considerations in the treatment of early-stage breast cancer in the elderly.Drugs Aging. 2010 Oct 1;27(10):791-800. doi: 10.2165/11584700-000000000-00000. Drugs Aging. 2010. PMID: 20883059 Review.
-
Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.Crit Rev Oncol Hematol. 2011 Aug;79(2):196-204. doi: 10.1016/j.critrevonc.2010.06.005. Epub 2010 Jul 23. Crit Rev Oncol Hematol. 2011. PMID: 20655243 Review.
Cited by
-
A nomogram for predicting breast cancer specific survival in elderly patients with breast cancer: a SEER population-based analysis.BMC Geriatr. 2023 Sep 25;23(1):594. doi: 10.1186/s12877-023-04280-8. BMC Geriatr. 2023. PMID: 37749538 Free PMC article.
-
Development and proof-of-concept of a multicenter, patient-centered cancer registry for breast cancer patients with metastatic disease-the "Breast cancer care for patients with metastatic disease" (BRE-4-MED) registry.Pilot Feasibility Stud. 2020 Feb 4;6:11. doi: 10.1186/s40814-019-0541-3. eCollection 2020. Pilot Feasibility Stud. 2020. PMID: 32042437 Free PMC article.
-
Healthcare providers' adherence to breast cancer guidelines in Europe: a systematic literature review.Breast Cancer Res Treat. 2020 Jun;181(3):499-518. doi: 10.1007/s10549-020-05657-8. Epub 2020 May 6. Breast Cancer Res Treat. 2020. PMID: 32378052 Free PMC article.
-
Awareness, offer, and use of psychosocial services by breast cancer survivors in Germany: a prospective multi-centre study.Arch Gynecol Obstet. 2023 Mar;307(3):945-956. doi: 10.1007/s00404-022-06665-3. Epub 2022 Jul 15. Arch Gynecol Obstet. 2023. PMID: 35835919 Free PMC article.
-
First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer.Arch Gynecol Obstet. 2020 Dec;302(6):1461-1467. doi: 10.1007/s00404-020-05771-4. Epub 2020 Sep 9. Arch Gynecol Obstet. 2020. PMID: 32902674 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical